Germany · Delayed Price · Currency is EUR Solasia Pharma K.K. Statistics
Total Valuation
FRA:9SO has a market cap or net worth of EUR 48.93 million. The enterprise value is 39.36 million.
| Market Cap | 48.93M |
| Enterprise Value | 39.36M |
Important Dates
The next estimated earnings date is Thursday, February 12, 2026.
| Earnings Date | Feb 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 259.80M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +21.82% |
| Shares Change (QoQ) | +14.57% |
| Owned by Insiders (%) | 2.13% |
| Owned by Institutions (%) | -3.80% |
| Float | 222.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.06 |
| PB Ratio | 4.73 |
| P/TBV Ratio | 4.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.81 |
| EV / Sales | 21.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -14.70 |
Financial Position
The company has a current ratio of 4.57, with a Debt / Equity ratio of 0.06.
| Current Ratio | 4.57 |
| Quick Ratio | 4.20 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.22 |
| Interest Coverage | -80.45 |
Financial Efficiency
Return on equity (ROE) is -89.69% and return on invested capital (ROIC) is -53.38%.
| Return on Equity (ROE) | -89.69% |
| Return on Assets (ROA) | -46.92% |
| Return on Invested Capital (ROIC) | -53.38% |
| Return on Capital Employed (ROCE) | -93.85% |
| Revenue Per Employee | 81,631 |
| Profits Per Employee | -449,719 |
| Employee Count | 23 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 0.54 |
Taxes
In the past 12 months, FRA:9SO has paid 11,518 in taxes.
| Income Tax | 11,518 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.76% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -47.76% |
| 50-Day Moving Average | 0.17 |
| 200-Day Moving Average | 0.19 |
| Relative Strength Index (RSI) | 52.78 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:9SO had revenue of EUR 1.88 million and -10.34 million in losses. Loss per share was -0.05.
| Revenue | 1.88M |
| Gross Profit | 1.39M |
| Operating Income | -10.19M |
| Pretax Income | -10.33M |
| Net Income | -10.34M |
| EBITDA | -10.75M |
| EBIT | -10.19M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 10.55 million in cash and 598,958 in debt, giving a net cash position of 9.95 million.
| Cash & Cash Equivalents | 10.55M |
| Total Debt | 598,958 |
| Net Cash | 9.95M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 10.34M |
| Book Value Per Share | 0.04 |
| Working Capital | 9.34M |
Cash Flow
In the last 12 months, operating cash flow was -2.67 million and capital expenditures -5,759, giving a free cash flow of -2.68 million.
| Operating Cash Flow | -2.67M |
| Capital Expenditures | -5,759 |
| Free Cash Flow | -2.68M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 73.93% |
| Operating Margin | -542.94% |
| Pretax Margin | -550.31% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:9SO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.82% |
| Shareholder Yield | -21.82% |
| Earnings Yield | -21.14% |
| FCF Yield | -5.47% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:9SO has an Altman Z-Score of 7.61 and a Piotroski F-Score of 3.
| Altman Z-Score | 7.61 |
| Piotroski F-Score | 3 |